Is Nintedanib/Vigat a life-saving drug or a potentially harmful drug?

Nintedanib(Nintedanib) is called "a life-saving drug for patients with pulmonary fibrosis" by many doctors, mainly because it can effectively delay the progression of the disease and slow down the decline of lung function. For progressive diseases such as idiopathic pulmonary fibrosis (IPF), which has no radical cure, nintedanib blocks abnormal fibroblast proliferation and collagen deposition by inhibiting the activity of multiple receptor tyrosine kinases related to fibrosis formation, thereby slowing down the hardening process of lung tissue, which has clinical significance for prolonging survival and improving quality of life. Therefore, nintedanib is considered a key disease-modifying agent in many clinical practices.

However, like all targeted drugs, nintedanib is not "risk-free." This drug may cause certain adverse reactions during long-term use. The most common side effects include diarrhea, nausea, loss of appetite, increased liver enzymes, and weight loss. Among them, gastrointestinal reactions are the most prominent and can generally be improved by adjusting the dosage or using auxiliary medications. A small number of patients may develop severe liver function abnormalities or coagulation problems, so liver function monitoring needs to be performed regularly during treatment. For patients with bleeding tendencies or who are taking anticoagulant drugs, doctors usually make a careful evaluation before deciding whether to use them.

In international clinical practice, the safety of nintedanib is generally considered controllable, and its adverse reactions are mostly dose-related and can be intervened through medical management. Compared with the high mortality rate of the disease itself, the risks of nintedanib are acceptable. As such, it is widely considered to be one of the few drugs currently available in the treatment of idiopathic pulmonary fibrosis that can significantly alter the course of the disease.

From the perspective of drug mechanism and clinical results, nintedanib is not only a "life-saving" anti-fibrotic drug, but also a powerful targeted drug that needs to be used with caution. For appropriate patient groups, standardized medication use and regular monitoring under the guidance of doctors are the key to fully exerting the efficacy and reducing risks.

Reference materials:https://en.wikipedia.org/wiki/Nintedanib